Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review

The central dilemma in treating patients with refractory or relapsed classical Hodgkin lymphoma (RRHL) is the developed resistance to chemotherapy. In recent years, significant advances have been made with the introduction of targeted immunotherapy such as brentuximab vedotin (BV) and nivolumab (NV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Macapagal, Sharina C, Lee, Hayoung, Abdul Jabbar, Javaria, Fjorden, Anna Caroline, Joseph, Irene Tresa, Kaur, Ramanpreet, Mostafa, Jihan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034766/
https://www.ncbi.nlm.nih.gov/pubmed/35481332
http://dx.doi.org/10.7759/cureus.23452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034766/
https://www.ncbi.nlm.nih.gov/pubmed/35481332
http://dx.doi.org/10.7759/cureus.23452

Ejemplares similares